RZLT

Rezolute Inc

Add to Watchlist

Advanced Chart

9.830

+0.18(1.865%)1D

Line

Candle

YTD

High

9.930

Open

9.450

VWAP

9.70

Vol

1.34M

Mkt Cap

911.51M

Low

9.320

Amount

13.01M

EV/EBITDA(TTM)

Total Shares

51.39M

759.32M

EV/OCF(TTM)

P/S(TTM)

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q4

FY2026Q3

FY2026Q2

-0.252

-3.08%

-0.231

-14.44%

-0.195

-11.36%

Estimates Revision

The market is revising No Change the revenue expectations for Rezolute, Inc. (RZLT) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 40.43%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+15.82%

In Past 3 Month

Stock Price

Go Up

+40.43%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast RZLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RZLT is 16.14 USD with a low forecast of 12.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 9.830

Low

12.00

Averages

16.14

High

20.00

Current: 9.830

Low

12.00

Averages

16.14

High

20.00

Citizens JMP

Outperform

maintain

$9 -> $17

2025-10-29

Reason

Citizens JMP

Price Target

$9 -> $17

2025-10-29

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Rezolute to $17 from $9 and keeps an Outperform rating on the shares. Rezolute remains on track to report top-line data in December from the Phase 3 sunRIZE study evaluating ersodetug in congenital hyperinsulinism, the analyst tells investors in a research note. Citizens remains confident in the potential for positive results driven by compelling efficacy and safety/tolerability demonstrated in the Phase 2b study.

Maxim

Buy

maintain

$15 -> $20

2025-09-19

Reason

Maxim

Price Target

$15 -> $20

2025-09-19

maintain

Buy

Reason

Maxim raised the firm's price target on Rezolute to $20 from $15 and keeps a Buy rating on the shares. The firm notes the shifting regulatory environment at FDA which, while inducing challenges for some drug categories, seems to have a more favorable view for rare disease, the analyst tells investors in a research note. Rezolute shares have also been rallying since late May stemming from multiple factors, initially with the completion of enrollment for the Phase 3 study of ersodetug in congenital hyperinsulinism announced on May 28, the firm added.

Maxim

NULL -> Buy

maintain

$15 -> $20

2025-09-18

Reason

Maxim

Price Target

$15 -> $20

2025-09-18

maintain

NULL -> Buy

Reason

Maxim raised the firm's price target on Rezolute to $20 from $15 and keeps a Buy rating on the shares.

JMP Securities

Jason Butler

Buy

Maintains

$8 → $9

2025-02-13

Reason

JMP Securities

Jason Butler

Price Target

$8 → $9

2025-02-13

Maintains

Buy

Reason

JMP Securities analyst Jason Butler raised the firm's price target on Rezolute to $9 from $8 and keeps an Outperform rating on the shares. Rezolute reported Q2 results and business updates, with the Phase 3 sunRIZE trial for ersodetug in congenital hyperinsulinism continuing to enroll, and progress remains on track to begin enrolling U.S. patients in the second quarter of 2025, the analyst tells investors in a research note. The firm looks to the outcome of the planned interim analysis for this trial in early 2Q25.

HC Wainwright & Co.

Douglas Tsao

Strong Buy

Reiterates

$14

2025-02-13

Reason

HC Wainwright & Co.

Douglas Tsao

Price Target

$14

2025-02-13

Reiterates

Strong Buy

Reason

Guggenheim

Debjit Chattopadhyay

Strong Buy

Reiterates

n/a

2025-02-10

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

n/a

2025-02-10

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Rezolute Inc (RZLT.O) is -10.48, compared to its 5-year average forward P/E of -2.92. For a more detailed relative valuation and DCF analysis to assess Rezolute Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.92

Current PE

-10.48

Overvalued PE

-0.93

Undervalued PE

-4.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

27.88

Current PS

0.00

Overvalued PS

185.60

Undervalued PS

-129.84